ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
6
views
0
references
Top references
cited by
1
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
2,681
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
. Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML. ASCO Annual Meeting 2017
Author(s):
R. STONE
,
R. COLLINS
,
MS Tallman
Publication date:
2017
Journal:
J Clin Oncol
Read this article at
ScienceOpen
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Alternative approaches to Alzheimer's Disease
Data availability:
Comments
Comment on this article
Sign in to comment
Similar content
2,681
AROG Pharmaceuticals. Investigator’s brochure. Crenolanib besylate (CP-868, 596-26)
Authors:
T. A. Dallas
Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML
Authors:
J Cortes
Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant
Authors:
Robert M. Collins
,
Hagop H. Kantarjian
,
Farhad Ravandi
…
See all similar
Cited by
1
Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?
Authors:
Brian Ball
,
Eytan Stein
See all cited by